Saturday 17 October 2026
Export GHRS’s income statement to Excel — free account
GH Research PLC
GHRS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 53.3%, free cash flow fell 66.6% and total debt fell 97.9%, each against the same quarter a year earlier.
18.16
0.65
−3.46%
Follow GHRS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(17.86%) | (21.04%) | (19.67%) | (18.79%) | |
| (17.11%) | (20.26%) | (18.94%) | (18.16%) | ||
ROIC |
(1,145.50%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(15.06%) | (17.35%) | (21.61%) | (17.47%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.67) | (0.72) | (0.74) | (0.78) | |
Free Cash Flow |
(41.79) | (43.67) | (45.83) | (51.84) | |
Capital Expenditures |
(0.13) | (0.12) | (0.18) | (0.14) | |
| Other line items | |||||
Cash ROIC |
(7.20%) | (7.79%) | (8.63%) | (7.18%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(103.16) | (131.14) | (180.85) | (257.14) | |
Operating CF/Net income |
0.97 | 0.90 | 0.81 | 0.83 | |
Depreciation/Fixed assets |
0.47 | 0.54 | 0.60 | 0.72 | |
Capex/Depreciation |
(0.39) | (0.36) | (0.51) | (0.38) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.67) | (0.71) | (0.74) | (0.78) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates